GoodRx Holdings earnings date
Want to see GDRX full AI Analyst Report?
GoodRx Holdings (GDRX) Q2 2026 Earnings Report
GDRX Q2 2026 EPS Results
- Actual EPS
- $0.08
- Consensus EPS
- $0.08
- Beat/Miss
- Met expectations
- One Year Ago EPS
- $0.09
GDRX Q2 2026 Revenue Results
- Actual Revenue
- $200.41M
- Expected Revenue
- $193.23M
- Beat/Miss
- Beat by +$7.18M
- YoY Revenue Growth
- -1.31%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/05/2026
- Time
- After Close
- Conference Call
- Wednesday, August 5, 2026
GoodRx Holdings's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call emphasized strong execution and visible, high-growth revenue engines (Pharma Direct and subscriptions) with meaningful beats and raised full-year guidance. These positives were tempered by declines in monthly active consumers, moderation of traditional prescription transaction revenue and limited disclosure of prescription-level KPIs during a strategic transition. Management framed the shifts as intentional investments in more durable, higher-LTV revenue streams and signaled confidence in sustained growth, while acknowledging some short-term metric and disclosure trade-offs.
GoodRx raised its full-year revenue guidance to $790–$805 million and its adjusted EBITDA guidance to $240–$250 million, citing strong first-half results (Q2 revenue $200.4M; adjusted EBITDA $63.7M; adj. EBITDA margin 31.8%) and an expectation that Pharma Direct and subscriptions will more than offset declines in prescription-transaction revenue in H2, with midpoint results returning the company to year-over-year revenue growth earlier than previously anticipated. Key Q2 metrics included Pharma Direct revenue of $61.6M (up 76% YoY, 18% QoQ; ~31% of revenue), prescription-transaction revenue of $106.4M, subscription revenue of $28.5M (up 39% YoY) and 5.0M monthly active consumers (down 12% YoY); subscription plans rose 14% YoY. Management also cited scale and engagement metrics supporting the outlook: >135 consumer-direct pricing programs, ~280M annual site visits, and e-commerce live at nearly 6,000 pharmacies.
- Strong Quarterly Financial ResultsRevenue of $200.4 million and adjusted EBITDA of $63.7 million in Q2 2026, with an adjusted EBITDA margin of 31.8%.
- Raised Full-Year Revenue and Profit GuidanceFull-year revenue guidance raised to $790 million–$805 million and adjusted EBITDA guidance raised to $240 million–$250 million; management expects to return to year-over-year revenue growth earlier than previously anticipated.
- Pharma Direct Rapid GrowthPharma Direct revenue of $61.6 million, up 76% year-over-year and 18% quarter-over-quarter; management now expects Pharma Direct to grow more than 70% year-over-year for the full year.
- Subscription Momentum and New Product LaunchSubscription revenue increased to $28.5 million, up 39% year-over-year; subscription plans increased 14% year-over-year. Launched GoodRx Companion in May (priced $14.99/month or $9.99/month with annual plan) offering 200 free generics, hundreds more under $10, online care, and other benefits.
- Platform Scale and ReachGoodRx cites over 280 million site visits annually and more than 135 consumer direct pricing programs; e-commerce capability live at nearly 6,000 pharmacies nationwide.
- Product and Channel DiversificationBusiness shifting toward higher-margin, durable revenue engines (Pharma Direct and subscriptions) and expanding into Employer Direct with a growing pipeline targeting Q4 and Q1 go-lives.
- Execution and Cost DisciplineManagement highlighted disciplined profitability while investing in strategic priorities and AI to improve workflows and operating leverage; leadership continuity with Justin Fengler (internal candidate) named CFO.
GDRX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | ―- | 0.09 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | 0.07- | 0.08 | ― | |
| Aug 05, 2026 | 2026 (Q2) | 0.080.08 | 0.09 | -11.11% (-0.01) | |
| May 06, 2026 | 2026 (Q1) | 0.070.07 | 0.09 | -22.22% (-0.02) | |
| Feb 25, 2026 | 2025 (Q4) | 0.090.09 | 0.09 | 0.00% (+0.00) | |
| Nov 04, 2025 | 2025 (Q3) | 0.090.08 | 0.08 | 0.00% (+0.00) | |
| Aug 06, 2025 | 2025 (Q2) | 0.100.09 | 0.08 | 12.50% (+0.01) | |
| May 07, 2025 | 2025 (Q1) | 0.100.09 | 0.08 | 12.50% (+0.01) | |
| Feb 27, 2025 | 2024 (Q4) | 0.090.09 | 0.08 | 12.50% (+0.01) | |
| Nov 07, 2024 | 2024 (Q3) | 0.090.08 | 0.06 | 33.33% (+0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

